Oragenics gains on toxicology data for COVID vaccine candidate study
22/12/2022 13:56
** Shares of drug developer Oragenics Inc OGEN.A gain ~44%
premarket to 19 cents
** Co says no toxicity signals or adverse events were found
in rabbits in a study evaluating the safety and immunogenicity
of its NT-CoV2-1 intranasal vaccine candidate
** Data to support its plans for regulatory filing to
initiate study in humans - OGEN
** Co expects to provide an update on its regulatory pathway
in Q1 2023
** The study was to evaluate the potential toxicity after
repeated intranasal administration at the maximal dose that the
company intends to use in humans
** Up to Wednesday's close, stock had fallen ~70% YTD
(Reporting by Sriparna Roy)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing